Raphael Pharmaceutical Inc.
RAPH· OTC
RAPHRaphael Pharmaceutical Inc.
Filed Aug 9, 2023 · 10-Q · 40 days after period end · 0001213900-23-065005
| Metric | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|
| Net Income | -$417.00K | -$627.00K | -$387.00K |
| EPS Diluted | $0.03 | $0.05 | $0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Raphael Pharmaceutical Inc. · CIK 1415397 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end
